Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Slides:



Advertisements
Similar presentations
Quantitative Synthesis II: Interactive Quiz Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.
Advertisements

Understanding heterogeneity in systematic reviews and met-analysis meta-analysis generates a single best estimate of effectmeta-analysis generates a single.
Meta-Analyses: Appropriate Growth Will G Hopkins Faculty of Health Science AUT University, Auckland, NZ Resources: Cochrane Reviewers Handbook (2006) at.
Significance testing and confidence intervals Ágnes Hajdu EPIET Introductory course
Pexelizumab for the Reduction of Infarction and Mortality in Coronary Artery Bypass Graft ll (PRIMO-CABG II) Trial Presented at The American College of.
The Bahrain Branch of the UK Cochrane Centre In Collaboration with Reyada Training & Management Consultancy, Dubai-UAE Cochrane Collaboration and Systematic.
A Comparison of Early Versus Late Initiation of Renal Replacement Therapy in Critically III Patients with Acute Kidney Injury: A Systematic Review and.
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
Overall and subgroup analysis If the OVERALL results show highly significant evidence of a worthwhile effect of treatment, but a few subgroups of the overview.
Meta-analysis: summarising data for two arm trials and other simple outcome studies Steff Lewis statistician.
Quantitative Synthesis II Prepared for: The Agency for Healthcare Research and Quality (AHRQ) Training Modules for Systematic Reviews Methods Guide
Exploring uncertainty in cost effectiveness analysis NICE International and HITAP copyright © 2013 Francis Ruiz NICE International (acknowledgements to:
ODAC May 3, Subgroup Analyses in Clinical Trials Stephen L George, PhD Department of Biostatistics and Bioinformatics Duke University Medical Center.
Challenges When Conducting Economic Evaluation Alongside Clinical Trials: Experience Of Economic Appraisal In Cardiovascular Disease Andrew Briggs University.
Design and Analysis of Clinical Study 12. Randomized Clinical Trials Dr. Tuan V. Nguyen Garvan Institute of Medical Research Sydney, Australia.
Critical Appraisal of Systematic Reviews Douglas Newberry.
Validity Lecture Overview Overview of the concept Different types of validity Threats to validity and strategies for handling them Examples of validity.
1 Canadian Institute for Health Information. Hospital Care for Heart Attacks Among First Nations, Inuit and Métis Released January 31,
The Bahrain Branch of the UK Cochrane Centre In Collaboration with Reyada Training & Management Consultancy, Dubai-UAE Cochrane Collaboration and Systematic.
Accounting for Clinical Heterogeneity in Comparative Effectiveness Research How Can One Examine a Trial for Heterogeneity of Treatment Effect (HTE)? The.
Are the results valid? Was the validity of the included studies appraised?
Chapter 5 Research Methods in the Study of Abnormal Behavior Ch 5.
Department of O UTCOMES R ESEARCH. Daniel I. Sessler, M.D. Michael Cudahy Professor and Chair Department of O UTCOMES R ESEARCH The Cleveland Clinic Clinical.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
CHP400: Community Health Program - lI Mohamed M. B. Alnoor Research Methodology STUDY DESIGNS Observational / Analytical Studies Present: Disease Past:
Sampling Techniques LEARNING OBJECTIVES : After studying this module, participants will be able to : 1. Identify and define the population to be studied.
Data Analysis in Systematic Reviews
 Is there a comparison? ◦ Are the groups really comparable?  Are the differences being reported real? ◦ Are they worth reporting? ◦ How much confidence.
Systematic Review Module 12: Presentation of Findings Melissa McPheeters, PhD, MPH Jeff Seroogy, BS Vanderbilt University EPC Joseph Lau, MD Thomas Trikalinos,
Systematic Review Module 7: Rating the Quality of Individual Studies Meera Viswanathan, PhD RTI-UNC EPC.
CHP400: Community Health Program - lI Research Methodology STUDY DESIGNS Observational / Analytical Studies Present: Disease Past: Exposure Cross - section.
Meta-analysis and “statistical aggregation” Dave Thompson Dept. of Biostatistics and Epidemiology College of Public Health, OUHSC Learning to Practice.
Successful Concepts Study Rationale Literature Review Study Design Rationale for Intervention Eligibility Criteria Endpoint Measurement Tools.
Presentation of Findings Interactive Quiz Prepared for: The Agency for Healthcare Research and Quality (AHRQ) Training Modules for Systematic Reviews Methods.
1 THE ROLE OF COVARIATES IN CLINICAL TRIALS ANALYSES Ralph B. D’Agostino, Sr., PhD Boston University FDA ODAC March 13, 2006.
Review of Research Methods. Overview of the Research Process I. Develop a research question II. Develop a hypothesis III. Choose a research design IV.
PH 401: Meta-analysis Eunice Pyon, PharmD (718) , HS 506.
Objectives  Identify the key elements of a good randomised controlled study  To clarify the process of meta analysis and developing a systematic review.
A Claims Database Approach to Evaluating Cardiovascular Safety of ADHD Medications A. J. Allen, M.D., Ph.D. Child Psychiatrist, Pharmacologist Global Medical.
BC Jung A Brief Introduction to Epidemiology - XIII (Critiquing the Research: Statistical Considerations) Betty C. Jung, RN, MPH, CHES.
EBM --- Journal Reading Presenter :呂宥達 Date : 2005/10/27.
Systematic Synthesis of the Literature: Introduction to Meta-analysis Linda N. Meurer, MD, MPH Department of Family and Community Medicine.
Quantitative Synthesis II Interactive Quiz Prepared for: The Agency for Healthcare Research and Quality (AHRQ) Training Modules for Systematic Reviews.
C-1 Efficacy of the Combination: Meta-Analyses Donald A. Berry, Ph.D. Frank T. McGraw Memorial Chair of Cancer Research University of Texas M.D. Anderson.
Effect of Rosiglitazone on the Risk of Myocardial Infarction And Death from Cardiovascular Causes Alternative Interpretations of the Evidence George A.
Zometa for Prostate Cancer Bone Metastases Protocol 039 Amna Ibrahim, M.D. Oncology Drug Products FDA.
Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:
Approaches to quantitative data analysis Lara Traeger, PhD Methods in Supportive Oncology Research.
Date of download: 6/2/2016 From: Quantitative Synthesis in Systematic Reviews Ann Intern Med. 1997;127(9): doi: /
Methodological quality assessment of observational studies Nicole Vogelzangs Department of Psychiatry & EMGO + institute.
From: Benefits and Harms of Statin Therapy for Persons With Chronic Kidney DiseaseA Systematic Review and Meta-analysis Ann Intern Med. 2012;157(4):
Systematic review of Present clinical reality
Arch Intern Med. 2004;164(13): doi: /archinte Figure Legend:
Meta-Analysis of a Possible Signal of Increased Mortality Associated with Cefepime Use Peter W. Kim, Yu-te Wu, Charles Cooper, George Rochester, Thamban.
NURS3030H NURSING RESEARCH IN PRACTICE MODULE 7 ‘Systematic Reviews’’
Benefits and Pitfalls of Systematic Reviews and Meta-Analyses
Francis KL Chan Department of Medicine & Therapeutics CUHK
Donald E. Cutlip, MD Beth Israel Deaconess Medical Center
Supplementary Table 1. PRISMA checklist
Heterogeneity and sources of bias
ALLHAT Do the SBP differences between the lisinopril and chlorthalidone arms explain the differences in CVD outcomes?
Association between risk-of-bias assessments and results of randomized trials in Cochrane reviews: the ROBES study Jelena Savović1, Becky Turner2, David.
Jun M, et al. Lancet 2010 Epub May 10
EAST GRADE course 2019 Introduction to Meta-Analysis
Publication Bias in Systematic Reviews
China PEACE risk estimation tool for in-hospital death from acute myocardial infarction: an early risk classification tree for decisions about fibrinolytic.
Acupuncture for Chronic Pain
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
Systematic Reviews and Meta-Analysis -Part 2-
Presentation transcript:

Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC

CER Process Overview

Learning objectives of this module Dealing with between-study heterogeneity Dealing with between-study heterogeneity Promise and danger of subgroup analyses Promise and danger of subgroup analyses Meta-regression Meta-regression Control rate meta-regression Control rate meta-regression

Homogeneity From Cochrane Database Syst Rev. 2000;(2):CD000505

Heterogeneity: Patellar resurfacing in total knee arthroplasty for pain J Bone Joint Surg Am. 2005;87(7):

Heterogeneity Diversity of studies in a meta-analysis Diversity of studies in a meta-analysis Typically abundant Typically abundant Arguably the most important role of meta- analytic methodologies is to quantify, explore, and explain between-study heterogeneity Arguably the most important role of meta- analytic methodologies is to quantify, explore, and explain between-study heterogeneity

Heterogeneity Methodological heterogeneity Pertains to specifics of study design and analysis (e.g., type of study, length of follow-up, proportion of dropouts and handling thereof) Pertains to specifics of study design and analysis (e.g., type of study, length of follow-up, proportion of dropouts and handling thereof) Clinical heterogeneity Pertains to differences in the populations, intervention and co-interventions, outcomes Pertains to differences in the populations, intervention and co-interventions, outcomes

Statistical heterogeneity Statistical heterogeneity exists when the results of the individual studies are not consistent among themselves Clinical heterogeneity Methodological heterogeneity Biases Chance Statistical heterogeneity

Clinical vs. statistical heterogeneity Clinical and methodological heterogeneity is abundant. Our aim is to explore it, and use these observations to formulate interesting hypotheses. Clinical and methodological heterogeneity is abundant. Our aim is to explore it, and use these observations to formulate interesting hypotheses. Often, but not always, clinical and methodological heterogeneity will result in a statistically significant test Often, but not always, clinical and methodological heterogeneity will result in a statistically significant test Chance, technical issues or biases may result in statistically significant results in heterogeneity tests Chance, technical issues or biases may result in statistically significant results in heterogeneity tests

META-REGRESSION modeling summary data OVERALL ESTIMATE combining summary data RESPONSE SURFACE modeling individual patient data SUBGROUP ANALYSES differentiating effects in subgroups

Promises of subgroup analyses

J Am Coll Card 1990

Mortality of thrombolytic therapy for AMI meantime to treatment (0-3 hours)

Mortality of thrombolytic therapy for AMI meantime to treatment (3.1-5 hours)

Mortality of thrombolytic therapy for AMI meantime to treatment ( hours)

Mortality of thrombolytic therapy for AMI meantime to treatment (> 10 hours)

Vit E and all cause mortality Ann Intern Med. 2005;142(1):37-46.

Hazards of subgroup analyses

From Fibrinolytic Therapy Trialists Collaborative Group: Indications for Fibrinolytic Therapy Lancet 343: 311,1994

ISIS-2. Lancet 1988;ii: Subgroup analyses

Beyond subgroup analyses: meta-regression

Subgroup analysis Ann Intern Med. 2005;142(1):37-46.

Univariate meta-regression Ann Intern Med. 2005;142(1):37-46.

Meta-regression: Zidovudine monotherapy vs. placebo ~τ 2

Multivariate meta-regression: Effect of Soy on LDL Dose Baseline LDL

Control Rate Meta-Regression Single covariate included is event rate in the control group (control rate) Single covariate included is event rate in the control group (control rate) – Control rate is surrogate for all baseline differences between the studies, in terms of baseline risk for the event of interest. – Can show that underlying risk of event (severity of illness) may explain differences in the treatment effect across studies

Control rate meta-regression in the streptokinase example Stat Med. 1998;17(17):

Two types of covariates in meta- regressions Study level covariates vs. participant level covariates Study level: presence/absence of blinding, intervention dose (in experimental studies) Study level: presence/absence of blinding, intervention dose (in experimental studies) Participant level: mean age, proportion of diabetics, mean intake of vitamin D (in observational studies) Participant level: mean age, proportion of diabetics, mean intake of vitamin D (in observational studies)

Spurious associations in meta- regressions and subgroup analyses Meta-regressions that use participant-level covariates can mislead, as they are susceptible to ecological fallacy Associations of treatment effect and participant-level covariates should be interpreted with caution See the quiz

Summary Subgroup analyses, meta-regressions and control-rate meta-regressions are tools to explore between-study heterogeneity. Do use them to understand your data. Subgroup analyses, meta-regressions and control-rate meta-regressions are tools to explore between-study heterogeneity. Do use them to understand your data. They are mostly hypothesis forming tools. Especially for meta-regressions on patient-level covariates, ecological fallacy may mislead. They are mostly hypothesis forming tools. Especially for meta-regressions on patient-level covariates, ecological fallacy may mislead. Beware when interpreting their results. Beware when interpreting their results.